Navigation Links
MedImmune Broadens Focus of Venture Capital Fund to Include New Therapeutic Areas
Date:1/7/2008

vancing science and medicine to help people live better lives and is wholly owned by AstraZeneca plc (LSE: AZN.L, NYSE: AZN). For more information, visit MedImmune's website at http://www.medimmune.com.

Forward Looking Statements

This press release contains certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, with respect to the operations, performance and financial condition of MedImmune, a member of the AstraZeneca Group. These forward-looking statements reflect management's current views and are based on current expectations and involve risks and uncertainties and may be influenced by factors that could cause actual outcomes and results to be materially different from those predicted. The risks and uncertainties associated with the business of the AstraZeneca Group are described in the reports and other documents filed by AstraZeneca plc with the Securities and Exchange Commission. These forward-looking statements are based on information currently available to AstraZeneca and AstraZeneca undertakes no obligation to update any such forward-looking statements included herein, except as otherwise may be required by applicable law or regulation.


'/>"/>
SOURCE MedImmune
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. MedImmune Licenses Reverse Genetics Technology to Novartis for Use in Influenza Vaccine Development and Production
2. MedImmune Celebrates Opening of New Pilot Lab at Gaithersburg Headquarters
3. MedImmune Recognized by Local Volunteer Organization for Its Employees Exceptional Commitment to Community Service within Montgomery County
4. MedImmune to Present RSV Surveillance and Cost-Effectiveness Data at American Academy of Pediatrics National Conference & Exhibition
5. AstraZeneca Bolsters Its Worldwide Biologics Division Through Integration of Cambridge Antibody Technology Into MedImmune
6. MedImmune Announces Seven Key Promotions and New Hires
7. Spherix Shareholders Support Companys Focus on Naturlose, Biotechnology
8. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
9. PDL BioPharma Announces Significant Strategic and Portfolio Changes to Focus on Antibody Discovery and Development
10. International Scientific Workshop Focuses on New Methods for Vaccine and Antibody Development
11. Pharmaceutical Product Launch: Commercially Focused R&D Increases Drugs Market Potential
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/16/2009)... Martek Biosciences Corporation (Nasdaq: MATK ) ... and fiscal year ended October 31, 2009. Revenues for ... $90.4 million in the fourth quarter of fiscal 2008. ... share, for the fourth quarter of fiscal 2009, a ... diluted share, in last year,s fourth quarter. The ...
(Date:12/16/2009)... among the Best in the Nation ,, ... proudly announces it has been granted Magnet(R) recognition ... Recognition Program(R). Magnet(R) is one of the highest ... can achieve, and places Hahnemann among the five ... achieved this prestigious distinction. ,, At 9:00 am ...
(Date:12/16/2009)... Cord Blood America, Inc. (OTC Bulletin ... preservation company ( http://www.cordblood-america.com ) focused on ... a biological insurance policy, to families nationwide and ... debt by a total of $1.4 million so ... total debt eliminated for the year now tops ...
(Date:12/16/2009)... Mass., Dec. 16 Decision Resources, one ... for pharmaceutical and healthcare issues, finds that, according ... Stelara and Abbott,s briakinumab (both interleukin inhibitors) will ... 2012 in the drug market for moderate to ... experience greater uptake, capturing nearly three times as ...
Breaking Biology Technology:Martek Announces Fourth Quarter and FY 2009 Financial Results 2Martek Announces Fourth Quarter and FY 2009 Financial Results 3Martek Announces Fourth Quarter and FY 2009 Financial Results 4Martek Announces Fourth Quarter and FY 2009 Financial Results 5Martek Announces Fourth Quarter and FY 2009 Financial Results 6Martek Announces Fourth Quarter and FY 2009 Financial Results 7Martek Announces Fourth Quarter and FY 2009 Financial Results 8Martek Announces Fourth Quarter and FY 2009 Financial Results 9Martek Announces Fourth Quarter and FY 2009 Financial Results 10Martek Announces Fourth Quarter and FY 2009 Financial Results 11Martek Announces Fourth Quarter and FY 2009 Financial Results 12Martek Announces Fourth Quarter and FY 2009 Financial Results 13Martek Announces Fourth Quarter and FY 2009 Financial Results 14Hahnemann University Hospital Granted Magnet(R) Status 2Hahnemann University Hospital Granted Magnet(R) Status 3Cord Blood America Says 2009 Debt Reduction Tops $10 Million 2Cord Blood America Says 2009 Debt Reduction Tops $10 Million 3In 2012, Stelara and Briakinumab Will Capture 22 Percent of the Biologics Share in the Moderate to Severe Psoriasis Drug Market 2In 2012, Stelara and Briakinumab Will Capture 22 Percent of the Biologics Share in the Moderate to Severe Psoriasis Drug Market 3
... HOUSTON, July 16 US Oncology Holdings, Inc. ... 2008 second quarter,financial results on Thursday, August 7, ... has been scheduled at 11:00,a.m., EDT, for the ... In this call, representatives of US Oncology,s management,team ...
... Sangamo,BioSciences, Inc. (Nasdaq: SGMO ) today announced ... results on Wednesday, July 23,2008, after the market closes. ... at 2:00 p.m. PT, which will be open to ... the company will review,the financial results and discuss other ...
... July 16 The Brazilian Sugarcane,Industry Association (UNICA) ... Policies" as another major report that highlights the,benefits ... reduction and,urges governments to level the playing field ... weeks, reports by diverse organizations such as FAO, ...
Other Biology Technology:Sangamo BioSciences Announces Second Quarter Conference Call and Webcast 2Sangamo BioSciences Announces Second Quarter Conference Call and Webcast 3Brazilian Sugarcane Industry: OECD Report Confirms Overall Benefits of Brazilian Sugarcane Ethanol 2Brazilian Sugarcane Industry: OECD Report Confirms Overall Benefits of Brazilian Sugarcane Ethanol 3
(Date:12/16/2009)... Dec. 8, 2009 National Instruments ... industrial measurement and control, and DENSO Robotics, ... using robotics technology, today announced their collaboration ... with DENSO robotic arms. The collaboration increases ... and flexible manufacturing applications. In today,s trend ...
(Date:12/15/2009)... LONDON, Dec. 15 The 2009 ... Innovation Award is presented to Sagem Securite ... Control systems. The award recognises the company,s ... continuous stewardship in offering novel, value-added products ... http://www.newscom.com/cgi-bin/prnh/20081117/FSLOGO ) ,, "Sagem Securite has ...
(Date:12/15/2009)... environmental impacts, social dynamics, and production levels are ... of an agroecosystem. Positive or negative, these factors ... social groups to continuously adapt farming and food ... learning theory suggests that knowledge is gained as ... are especially valuable for environmental and agricultural educators ...
Breaking Biology News(10 mins):National Instruments and DENSO Robotics Collaborate to Address New Applications in Industrial Robotics 2National Instruments and DENSO Robotics Collaborate to Address New Applications in Industrial Robotics 3National Instruments and DENSO Robotics Collaborate to Address New Applications in Industrial Robotics 4National Instruments and DENSO Robotics Collaborate to Address New Applications in Industrial Robotics 5Frost & Sullivan Recognises Sagem Securite for its Innovative Automated Border Control Systems 2Frost & Sullivan Recognises Sagem Securite for its Innovative Automated Border Control Systems 3Frost & Sullivan Recognises Sagem Securite for its Innovative Automated Border Control Systems 4Experiential learning teaches change and adaptation 2Arena Pharmaceuticals to Host Conference Call and Webcast on Friday September 18 2009 to Discuss Results from the BLOSSOM Phase 3 Trial of Lorcaser 5016 1Arena Pharmaceuticals to Host Conference Call and Webcast on Friday September 18 2009 to Discuss Results from the BLOSSOM Phase 3 Trial of Lorcaser 5016 2Arena Pharmaceuticals to Host Conference Call and Webcast on Friday September 18 2009 to Discuss Results from the BLOSSOM Phase 3 Trial of Lorcaser 5016 3Study Links Epilepsy to Brain Protein 57562 1Lack of Insurance to Blame for Almost 45 000 Deaths 3A Study 57560 1Lack of Insurance to Blame for Almost 45 000 Deaths 3A Study 57560 2Lack of Insurance to Blame for Almost 45 000 Deaths 3A Study 57560 3
... Columbia University's Mailman School of Public Health, the Centers ... Research Center have discovered a key mechanism by which ... identification of an amino acid sequence in Filoviruses that ... described in the December 2006 issue of The FASEB ...
... cheap, quick and copyright-respecting way to turn existing print ... in an experimental beta version for free download, is ... the most popular computer operating systems. , "Brain ... says Gully A.P.C. Burns, a specialist in neuroinformatics who ...
... levels of the virus associated with cervical cancer can ... according to a study published in the November 2006 ... Anthony Gunnell, a medical biostatistician and epidemiologist and colleagues ... exams of women with non-invasive cervical cancer in situ ...
Other Biology News:Researchers discover key mechanism by which lethal viruses Ebola and Marburg cause disease 2Beyond the book: Software automates access to brain atlases 2Beyond the book: Software automates access to brain atlases 3High HPV concentrations combined with smoking significantly raise risks of cervical cancer 2High HPV concentrations combined with smoking significantly raise risks of cervical cancer 3
... NOBLE BSA-Free Stabilizer is a bovine ... It is an aqueous solution ... a MOPS buffer (3-(N-Morpholino) propanesulfonic acid), ... a combination of 0.02% methylisothiazolone and ...
These 96-well 0.2 ml thin-wall PCR plate caps are caps that are used to seal 96-well, 0.2 ml thin-wall PCR plates. Supplied as 300 caps....
... software with the DeCypher Engine accelerator cards to ... perform searches like these from your desktop: ... under 6 days Align BAC-sized queries ... HMM analysis to compare 100,000 sequences to PFAM ...
Mouse monoclonal antibody to FMN2 - formin 2...
Biology Products: